Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 675.50
Bid: 675.00
Ask: 676.00
Change: 2.00 (0.30%)
Spread: 1.00 (0.148%)
Open: 674.00
High: 678.50
Low: 672.50
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Venture Fund

8 Nov 2012 07:01

null

Tate & Lyle to expand its global innovation programme through a new £30 million venture fund (Tate & Lyle Ventures II)

Tate & Lyle PLC announced today an investment of up to £30 million over an eight-year period in a new venture capital fund, building on Tate & Lyle's existing venture fund activities.

The new Fund will invest in start-ups and expansion-stage companies in both developed and emerging markets in food sciences and enabling technologies in line with Tate & Lyle's strategy to grow in speciality food ingredients.

The new Fund will be formally launched on 1 January 2013. As with Tate & Lyle's first venture fund, which was launched in April 2006, the new Fund will be independently led and managed by Simon Barnes and David Atkinson.

"This is an important investment in our global innovation programme and represents another step in building Tate & Lyle's platform for long-term growth" said Karl Kramer, President, Innovation and Commercial Development, Tate & Lyle.

Kramer added, "We have seen with our first Fund how beneficial a corporate venturing capability can be. The combination of the new Fund and our internal Open Innovation team will enable us to access the full spectrum of new ideas, technologies and opportunities in the global food science and investment community. This is an investment for long-term growth and, ultimately, will help us deliver more innovative solutions for our customers".

David Atkinson, Tate & Lyle Ventures said, "We are continuing to see a real change in consumer attitudes towards health and nutrition and in particular the growing interest in functional foods. Busy lives, an ageing population and rapid urbanization in emerging markets mean that consumers across the world are looking to food to offer lifestyle solutions and bring added benefits such as fortification and enrichment. New technologies will be instrumental in this convergence as the world's major food companies increasingly reposition themselves with a focus on innovation and health."

Simon Barnes, Tate & Lyle Ventures said, "We will be looking to invest in companies based on strong intellectual property and with strong management teams. As with the first Fund, the independent structure of the new Fund means we can leverage Tate & Lyle's core expertise in helping us to build our portfolio whilst retaining the ability to manage the investments in accordance with sound venture capital principles."

Notes to Editors:

1. For more details on the fund, please contact:

David Atkinson - david.atkinson@tateandlyleventures.com

Simon Barnes - simon.barnes@tateandlyleventures.com

2. The fund will have £30 million of committed capital at closing and is looking to back 8-10 deals over several rounds of finance. Optimal investment sizes are between £2-5 million.

3. Like the first Fund, Tate & Lyle Ventures II will be managed by Circadia Ventures LLP of which Simon Barnes and David Atkinson are the Managing Partners. Circadia Ventures LLP was founded in 2006 and is authorized and regulated by the Financial Services Authority. Simon and David's biographies are:

Simon Barnes

Simon Barnes has a background in life sciences venture capital, first with the London office of Atlas Venture and subsequently with GIMV Venture Capital. He has focused since 1998 on investing in university spin-outs. Simon was trained as a scientist and has a first class degree in Natural Sciences and a PhD from the University of Cambridge. Together with David Atkinson, Simon co-founded Circadia Ventures LLP in 2006. Simon currently sits on the boards of Allylix Inc., Aquapharm BioDiscovery Ltd., Fugeia NV and Lumora Ltd.

David Atkinson

David Atkinson has held a number of senior management positions in the City, with 14 years' experience in equity research focusing on the food processing industry, whilst he alsoco-founded Stamford Partners, the European food and drink industry advisory firm. Together with Simon Barnes, David co-founded Circadia Ventures LLP in 2006. David currently sits on the boards of BioFilm Holdings Ltd., Fugeia NV and Lumora Ltd.

Copyright Business Wire 2012

Date   Source Headline
5th Aug 20193:00 pmRNSIssue of Debt
1st Aug 20192:00 pmRNSTotal Voting Rights
25th Jul 201912:58 pmRNSResult of AGM
18th Jul 20193:00 pmRNSDirector/PDMR Shareholding
17th Jul 20197:02 amRNSChange to Executive Committee
1st Jul 201912:40 pmRNSBlock listing Interim Review
1st Jul 201912:38 pmRNSTotal Voting Rights
1st Jul 201912:00 pmRNSDirector/PDMR Shareholding
10th Jun 201911:30 amRNSAnnual Financial Report
5th Jun 20199:52 amRNSHolding(s) in Company
5th Jun 20199:34 amRNSDirector/PDMR Shareholding
3rd Jun 201910:42 amRNSTotal Voting Rights
29th May 20194:00 pmRNSDirector/PDMR Shareholding
28th May 20194:12 pmRNSDirector/PDMR Shareholding
23rd May 20197:00 amRNSFinal Results
9th May 201911:00 amRNSDirectorate Change
1st May 201910:00 amRNSTotal Voting Rights
1st Apr 20194:17 pmBUSTotal Voting Rights
1st Apr 20193:45 pmBUSHolding(s) in Company
1st Mar 201911:21 amBUSTotal Voting Rights
27th Feb 20191:00 pmBUSHolding(s) in Company
7th Feb 20197:00 amBUSTrading Statement
1st Feb 201911:40 amBUSTotal Voting Rights
3rd Jan 20192:00 pmBUSDirector/PDMR Shareholding
2nd Jan 20193:53 pmBUSBlock listing Interim Review
6th Dec 201811:32 amBUSDirector/PDMR Shareholding
5th Dec 20182:22 pmBUSDirector/PDMR Shareholding
3rd Dec 20183:34 pmBUSTotal Voting Rights
19th Nov 20187:00 amBUSDirectorate change
8th Nov 20187:00 amBUSHalf-year Report
1st Nov 201812:20 pmBUSTotal Voting Rights
5th Oct 20182:05 pmBUSDirector/PDMR Shareholding
1st Oct 20182:25 pmBUSTotal Voting Rights
21st Sep 201811:43 amBUSDirector/PDMR Shareholding
10th Jul 201811:21 amBUSDirector/PDMR Shareholding
10th Jul 201810:50 amBUSHolding(s) in Company
2nd Jul 20183:42 pmBUSTotal Voting Rights
2nd Jul 20183:11 pmBUSBlock listing Interim Review
28th Jun 20185:37 pmBUSDirector/PDMR Shareholding
21st Jun 201812:34 pmBUSAnnual Financial Report
14th Jun 20185:34 pmBUSDirector/PDMR Shareholding
6th Jun 20186:21 pmBUSDirector/PDMR Shareholding
1st Jun 201812:44 pmBUSTotal Voting Rights
29th May 20185:54 pmBUSDirector/PDMR Shareholding
24th May 20187:00 amBUSFinal Results
1st May 20181:00 pmBUSTotal Voting Rights
18th Apr 201812:27 pmBUSDirector/PDMR Shareholding
17th Apr 20187:00 amBUSImran Nawaz Appointed Chief Financial Officer of Tate & Lyle PLC
13th Apr 20181:48 pmBUSDirector Declaration
5th Apr 20184:31 pmBUSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.